Laurus Labs Limited

NSE LAURUSLABS.NS

Laurus Labs Limited Free Cash Flow for the year ending March 31, 2024: USD -1.51 M

Laurus Labs Limited Free Cash Flow is USD -1.51 M for the year ending March 31, 2024, a -432.50% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Laurus Labs Limited Free Cash Flow for the year ending March 31, 2023 was USD 455.05 K, a -89.91% change year over year.
  • Laurus Labs Limited Free Cash Flow for the year ending March 31, 2022 was USD 4.51 M, a -25.30% change year over year.
  • Laurus Labs Limited Free Cash Flow for the year ending March 31, 2021 was USD 6.04 M, a -63.65% change year over year.
  • Laurus Labs Limited Free Cash Flow for the year ending March 31, 2020 was USD 16.62 M, a 166.08% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
NSE: LAURUSLABS.NS

Laurus Labs Limited

CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
IPO Date Dec. 19, 2016
Location India
Headquarters Serene Chambers
Employees 6,007
Sector Health Care
Industries
Description

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Similar companies

DEEPAKNTR.NS

Deepak Nitrite Limited

USD 27.05

0.71%

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

IEX.NS

Indian Energy Exchange Limited

USD 1.93

3.86%

DIXON.NS

Dixon Technologies (India) Limited

USD 188.04

2.93%

DIVISLAB.NS

Divi's Laboratories Limited

USD 69.21

4.65%

StockViz Staff

January 15, 2025

Any question? Send us an email